ASHLEY GOODALL: Open Payments
NPI 1851619605 · ROWLETT, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,129 in 117 payments from 31 companies in 2025. Trend: 2023 $1,498 · 2024 $1,563 · 2025 $2,129
Food & beverage: $2,129
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 12 | $231 |
| PFIZER INC. | 9 | $185 |
| ABBVIE INC. | 12 | $158 |
| Amgen Inc. | 14 | $136 |
| Dexcom, Inc. | 6 | $135 |
| Corcept Therapeutics | 3 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $133 |
| Antares Pharma, Inc. | 7 | $122 |
| Otsuka America Pharmaceutical, Inc. | 4 | $98 |
| Lilly USA, LLC | 4 | $79 |
Products named: Ozempic, Dexcom G6 Transmitter, Korlym, TRINTELLIX, XYOSTED, JARDIANCE, REXULTI, ELIQUIS.
Industry payments across TX — which companies pay providers there.
